Biologika als Erstlinientherapie bei chronisch entzündlichen Darmerkrankungen – pro

chronisch entzündliche Darmerkrankungen - Biologika - Erstlinientherapie

chronic inflammatory bowel disease - biologicals - first-line therapy

Literatur

• 1 Faubion Jr W A, Loftus Jr E V, Harmsen W S. et al . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.  Gastroenterology. 2001;  121 255-260
• 2 Herrlinger K, Stange E F. Treatment of Crohn’s disease: step-up or top-down?.  Dtsch Med Wochenschr. 2010;  135 1694-1698
• 3 Feagan B G, Panaccione R, Sandborn W J. et al . Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study.  Gastroenterology. 2008;  135 1493-1499
• 4 de Pineton Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel J F. Clinical implications of mucosal healing for the management of IBD.  Nat Rev Gastroenterol Hepatol. 2010;  7 15-29
• 5 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease.  Nat Rev Gastroenterol Hepatol. 2010;  7 79-85